A semi-automatic method for delineating contrast-agent enhancing brain tumor, called quantitative delta T1 (qDT1), was compared to central reader analysis of clinical trial data. The qDT1 method demonstrated equivalence with expert reads for determination of early tumor progression and proved superior for further distinguishing responders from non-responders/non-progressors at the week 8 time point. Using qDT1 provides a solution to the high percentage of intra- and inter-observer disagreements, while being easier to use and more reliable for the daily clinical assessment of tumor response to therapy, as well as for large scale clinical trials.
This abstract and the presentation materials are available to members only; a login is required.